About US
Contact us
-
Regeneron wins another FDA nod for powerhouse Eylea despite trial flopsFour years afterscoringan approval to treat diabetic retinopathy—a disease that strikes more than a third of those with diabetes and is the primary cause of blindness in the U.S.—Regeneron’s Eylea ha2023/2/7
-
Looking forward to Humira biosimilar launch, Teva leans on Ajovy and Austedo as revenues sinkTeva's new CEO Richard Francis has his work cut out as the company seeks to recover from a revenue slide. Thanks to declines for several of its offerings, Tevaglobalsales slipped 5% year2023/2/7
-
Amgen aims to make the most of Amjevita's head start amid broader biosim lull, Lumakras missThe biosimilars business is tough to conquer, but Amgenhopes its newest launch can help it overcome a slowdown for its older copycat products and a lull for new cancer med Lumakras. Boast2023/2/3
-
GSK's oral anemia drug Jesduvroq scores partial FDA nod after 2 rivals suffered rejectionsTurns out, the third time is the charm. After two prior FDA rejections for oral anemia drugs in the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) drug class, GSK’s dapro2023/2/3
-
Novo's Rybelsus comes into its own as Wegovy shakes off supply constraintsDespite pandemic headwinds at launch, Novo Nordisk’s oral semaglutide med Rybelsus has come into its own. For all of 2022, Rybelsus sales more than doubled to 11.29 million Danish kroner2023/2/1
-
BioNTech wraps up construction at German plant, expects full operations to start later this yearEven as mRNA specialist BioNTechplants its manufacturing flag on continents around the globe, the company is still advancing production capabilities at home. Thursday, BioNTechsaid itfini2023/2/1
-
JPM23: Viatris lays out plans to become ophthalmology leader and pull down $1B in eye care salesTwo years afterforming throughthe merger ofPfizer's Upjohn and Mylan, Viatris has carved out new ambitions to become a global leader in eye care. At the same time, the company is working to grow beyo2023/1/17
-
CordenPharma inks peptide deal, plans $210M production expansionGerman CDMO CordenPharma has inked amultiyear dealto manufacture large-volume peptides at its Colorado facility. The agreement, which the company valued at a potential $1 billion, will su2023/1/17
-
AstraZeneca's first-in-class rescue inhaler Airsupra wins FDA nod—but only for adult useAs AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. Wednesday, the British drugmaker2023/1/12
-
JPM23: Is GSK’s 15-day accelerated approval withdrawal the new normal? Hear FDA commissionerIn a surprising move, GSK recently pulled multiple myeloma therapy Blenrep off the U.S. market just 15 days after the drug flunked a confirmatory trial. The product pull came at the request of the FD2023/1/12